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termine their impact on function, quality of life, men-
tal health and use of healthcare resources. 
This article describes in detail the design, metho -
dology and planned analyses of EpiReumaPt.
Recruitment started in September 2011 and finished
in December 2013. This study involved a three-stage
approach. The first step was a face-to-face survey per-
formed by trained interviewers at the household of
ABSTRACT
Rheumatic and musculoskeletal diseases (RMD) are
prevalent and a leading cause of disability and con-
sumption of healthcare and social resources.
EpiReumaPt is a national population-based survey de-
veloped by the Portuguese Society of Rheumatology
that aimed to estimate the prevalence of RMDs and de-
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knowledge and awareness of RMDs in Portugal. SPR
combines its scientific expertise with excellent rela-
tionships with other stakeholders, including govern-
mental and regulatory authorities and the pharma-
ceutical industry10. As a result, during the last few
years, SPR has attained major achievements as a scien -
tific society, for instance, with the development of na-
tional health registries, data collection and ana lyses of
large databases7,11. SPR had previously recogni zed that
an epidemiologic study of RMDs was an unmet need
in Portugal, but it had been repeatedly postpo ned due
to financial constraints. In 2011, the joint efforts of
SPR, governmental entities, the pharmaceutical in-
dustry and the commitment of the investigators of the
study allowed the development of the first large epi-
demiologic and population-based study of RMDs in
Portugal (EpiReumaPt). The main aim of EpiReumaPt
was to estimate the prevalence of RMDs, namely hand,
knee and hip osteoarthritis (OA), low back pain (LBP),
rheumatoid arthritis (RA), fibromyalgia (FM), gout,
spondyloarthritis (SpA), periarticular diseases (PD),
systemic lupus erythematosus (SLE), polymyalgia
rheumatica (PMR), and osteoporosis (OP) in the adult
Portuguese population. The secondary aims were to
determine the impact of RMDs on function, quality of
life, mental health, work status and use of health care
resources, in line with the objectives of the PNCDR.
The rigorous methodology and large scale of the study
were unprecedented in Portugal represents an impor-
tant contribution of rheumatology as a specialty mo -
ving towards excellence standards of epidemiological
and clinical research in Portugal. 
This paper describes in detail the methodology of
EpiReumaPt, including its objectives and study design,
how recruitment was conducted, and gives the first in-
sight into study participation and data preparation for
analyses. Specific practical issues and management
strategies of EpiReumaPt are addressed in another ar-
ticle published in the same issue of this Journal12. 
GEOGRAPhICAl SETTING Of EPIREUmAPT
Portugal is a Southwestern European country that in-
cludes the mainland and the two archipelagos, Madeira
and Azores. According to the 2011 census, Portugal
has a resident population of 10,562,178 inhabitants,
of which 8 million are adults (4,072,122 men and
4,585,118 women)13. As in other European countries,
the age gap between young and older people increased
in the last decade. In fact, according to Portuguese
CENSUS the percentage of young adults (18-29 years-
10,661 subjects, who where randomly selected by a
stratified multistage sampling. A highly sensitive
screening questionnaire for RMDs was used. Second-
ly, participants who screened positive (64%) for at least
one RMD, as well as 20% of individuals with a negati -
ve screening, were invited for assessment by a rheu -
mato logist. In total, 3,877 subjects participated in this
second phase, where they were also invited to donate
a blood sample to be stored at the Biobanco-IMM. His-
tory and physical examination, followed by appropria -
te laboratory and imaging tests were performed. At the
end of the visit, the rheumatologist established a
diagno sis. Finally, a team of three experienced rheuma-
tologists reviewed all the clinical data and defined the
diagnoses according to previously validated criteria. 
The EpiReumaPt dataset, containing data from seve -
ral questionnaires, various clinical measurements and
information from laboratory and imaging tests, com-
prises an invaluable asset for research. The large
amount of information collected from each participant
and the large number of participants, with a wide age
range covering and being representative of the adult
population from the entire country, makes EpiReu -
maPt the largest study of RMDs performed in Portugal.
Keywords: EpiReumaPt; Epidemiology; Rheumatic
diseases; Methodology; Portugal; Study design.
INTRODUCTION
Rheumatic and Musculoskeletal diseases (RMDs) are
among the most common diseases managed at the pri-
mary health care level. They are leading causes of disa -
bility in developed countries and consume a large
amount of health and social resources 1-3. 
As opposed to several other European countries, the
prevalence of RMDs in Portugal is poor-defined due
to the lack of well-designed and consistent epidemio-
logic studies1-7. A nationwide epidemiological study
was the way to fulfill this unmet need, and it was also
a specific objective of the National Program Against
Rheumatic Diseases (PNCDR) (2004-2014)8. This pro-
gram was part of the National Health Plan for
2004/2010 and a contribution of the Portuguese Go -
vernment to the international “Bone and Joint Decade
2000/2010”, an initiative of the United Nations,
suppor ted by the World Health Organization9.
The Portuguese Society of Rheumatology (SPR) is a
scientific society that has the mission to increase the
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Exclusion criteria were: residents in hospitals, nurs-
ing homes, military institutions or prisons, and indi-
viduals unable to speak Portuguese or unable to com-
plete the questionnaire, despite being aided 7.
STUDy DESIGN
EpiReumaPt is a national, cross-sectional, population-
based study conducted from September 2011 to De-
cember 2013 and involved a three-stage approach
(Figure 2).
First phase (RMD disease screening): face to face
interviews were performed by interviewers (non-
physicians, trained for this purpose), at each partici-
pant’s household. The interviews were conducted with
a Computer Assisted Personal Interview (CAPI) sys-
tem. A detailed and comprehensive questionnaire in-
cluding a screening for RMDs symptoms was applied
(available upon request). Participants were inquired
about self-reported RMD and subsequently about spe-
cific rheumatic and musculoskeletal symptoms. Fi-
nally, an algorithm for the screening of specific RMD
was applied. In addition, subjects were inquired about
socio-demographics, socio-economics, life style,
healthcare resources consumption, functional status,
quality of life, mental health, work status, and other
diseases. 
An individual was considered to have a positive
screening if the subject mentioned a previously known
RMD, if any of the algorithms in the screening ques-
tionnaires was positive, or if the subject reported mus-
cle, vertebral or peripheral joint pain in the previous
4 weeks. The overall performance of the screening al-
gorithm was evaluated (the gold standard was consi -
dered the final diagnosis after revision, see phase 3)
and the overall sensitivity of the screening question-
naire for RMD was 98%, with a specificity of 22%. The
positive predictive value was 85% and the negative
predictive value was 71%. 
Second phase (RMD Diagnosis): In order to de-
termine the RMD diagnosis, a clinical observation by
a rheumatologist was offered to subjects who screened
positive for at least one RMD and also to 20% of indi-
viduals with no rheumatic complaints, during the first
phase of the study. In total, 95 rheumatologists were in-
volved. They were blinded to the screening results and
received instructions on how to conduct the history
and physical examination, following a standardized
protocol. They could also request for new laboratory
and imaging tests during the appointment. Participants
were asked to bring their previous imaging and labo-
old) decreased from 16% in 2001 to 5.1% in 2011.
Among the elderly population (>65 years-old) the
oppo site trend was observed, rising from 16% in 2001
to 19% in 201113.
Portugal is divided in 7 regions according to the
Nomenclature of Territorial Units for Statistics II (NUTS
II) - Norte, Centro, Lisboa e Vale do Tejo, Alentejo, Algarve,
Região Autónoma dos Açores (the Azores) and Região
Autónoma da Madeira (Madeira). At the NUTS II level,
the Norte region has the largest population density
(34.7 %) followed by Lisboa e Vale do Tejo (26.6%) and
Centro (22.4%) (Figure 1). The others NUTS II regions
(Alentejo, Algarve, the Azores and Madeira) encompass
small towns and villages with a lower population den-
sity and higher desertification rates.
mATERIAlS AND mEThODS
STUDy POPUlATION
The study population was composed by non-institu-
tionalized adults (≥18 years-old) living in private
households in Portugal (Mainland and the Islands -
Madeira and the Azores). 
fIGURE 1. Portuguese population density distribution 
according to NUTS II 
NUTS II- Nomenclature of Territorial Units for Statistics 
(Norte, Centro, Alentejo, Algarve, Lisboa, Madeira and the
Azores)
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ratory results. Computed assisted software specifical-
ly designed for the study was used to support clinical
appointment registries. First, the rheumatologist col-
lected the clinical history in a standardized way and
placed all the diagnostic hypotheses. The hypotheses
where then selected in a dedicated EpiReumaPts soft-
ware and specific questions related to the possible
diagno sis were asked. For each RMD that was studied
in EpiReumaPt, the research team developed specific
questions, including those related to validated classi-
fication criteria that should be completed, according to
the diagnostic hypothesis previously selected. Finally,
the physician had to go through a checklist, in order
to verify if the patient fulfilled the pre-established dia -
gnostic criteria (see case definition). If needed, labo-
ratory testing and radiographic examinations were per-
formed at the participant’s Primary Care Center in or-
der to confirm the diagnostic hypothesis. 
Positive RMD screening (n=7,451)+Negative RMD screening (n=3,210)
EpiReumaPt selected samplen=10,6611st phase: RMD screeningEligible population:Portuguese Population ≥ 18 years oldn=7,719,986 (Census 2001)
Face-to-face interview(n=10,661)
Positive RMD screening (n=7,451)+≈20% without RMD screening (n=701)2nd phase elegible population
Positive RMD screening (n=3,653)+Negative RMD screening (n=224)2nd phase: RMD DiagnosticRheumatologist appointment(n=3,877)
3nd phase: RMD Diagnostic Revisionn=3,877Subjects with RMD diagnosis (n=3,198)+
Subjects without RMD diagnosis (n=679)
Positive RMD screening (n=3,798)+Negative RMD screening (n=477)2nd phase Drop-outsImpossible to contact/faults(n=4,275)
Positive RMD screening (n=7,451)
+
Negative RMD screening (n=3,210)
EpiReumaPt selected sample
n=10,661
1st phase: RMD screening
Eligible population:
Portuguese Population ≥ 18 years old
n=7,719,986 (Census 2001)
Face-to-face interview
(n=10,661)
Positive RMD screening (n=7,451)
+
≈20% without RMD screening (n=701)
2nd phase elegible population
Positive RMD screening (n=3,653)
+
Negative RMD screening (n=224)
2nd phase: RMD Diagnostic
Rheumatologist appointment
(n=3,877)
3nd phase: RMD Diagnostic Revision
n=3,877
Subjects with RMD diagnosis (n=3,198)
+
Subjects without RMD diagnosis (n=679)
Positive RMD screening (n=3,798)
+
Negative RMD screening (n=477)
2nd phase Drop-outs
Impossible to contact/faults
(n=4,275)
fIGURE 2. Flowchart of recruitment in the EpiReumaPt Study
RDM: Rheumatic and Musculoskeletal diseases
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The clinical assessments were performed at the Pri-
mary Care Center of the participant’s neighborhood. A
mobile van, fully equipped, was used to perform ima -
ging and laboratory tests: X-ray of the affected joint(s),
peripheral dual energy X-ray and blood tests. A mul-
tidisciplinary team with a rheumatologist, an X-Ray
technician, a nurse, a staff coordinator and a driver
supported the clinical visits. 
Third phase (RMD Diagnostic Validation):
Using the results from the laboratorial and imaging
tests previously requested, a team of three experienced
rheumatologists reviewed all the clinical data from
each participant in order to validate the diagnostic de-
cision made in the second phase. Moreover, when a
patient was referred to a rheumatology center due to a
suspected inflammatory disease in the second phase,
follow-up information from that center was also used.
A specific protocol was developed to support these
tasks. When data were insufficient to fulfill interna-
tional classification criteria, a meeting with 5 rheuma-
tologists took place in order to reach an agreement on
the final diagnosis based on expert opinion. When
doubts persisted regarding the final diagnosis, the
opinion of the rheumatologist that performed the cli -
nical assessment (second phase) prevailed. Diagnostic
agreement between the 3 reviewers was 98.3% with a
Cohens K coefficient of 0.87 (95%CI from 0.83 to
0.91).
SAMPLING AND RECRUITMENT
The sample size was calculated by taking into account
the prevalence of RA, as described in the study proto-
col 7. The participants were selected through a process
of multistage random sampling. The sample was stra -
tified according to the Portuguese statistic regions
NUTS II in the 2001 Census and the size of the popu-
lation (less than 2,000; 2,000-9,999; 10,000-19,999;
20,000-99,999; and ≥100,000 inhabitants). The num-
ber of participants of each stratum was proportional to
the actual distribution of the population. In Madeira
and the Azores we increased the sample size (over-
sampling) to allow separate analyses in these regions. 
Candidate households were selected through a ran-
dom route process: sampling points were randomly
selected on the maps of each locality, where the inter-
viewer began a systematic step count (defined for each
locality according to its size), granting each household
and each individual an equal probability of being cho-
sen. Dwellings with commercial or industrial purpo -
ses, private or public institutions and visibly unoccu-
pied buildings were considered ineligible. In the
household, the individual over 18 years old with per-
manent residence and with the most recently com-
pleted birthday was selected. The population recruit-
ment was led by Centro de Estudos e Sondagens de
Opinião da Universidade Católica Portuguesa (CESOP-
UCP). Each interviewers  team worked daily on the
field (week and weekend) in groups of 4 or 5 elements,
and covering a different route. When no subject was
found in a first visit of the selected household, he/she
could not be replaced, unless that household had been
visited in three different times, including evenings and
weekends. 
Quality control of interviews was performed
through a random evaluation of the interviews and
recheck of the participants’ eligibility criteria. Specifi-
cally, each interviewer had 25% of his interviews sub-
mitted to a quality control telephone contact, in order
to assess the reliability of the answers. The selection of
households and the selection of respondents were also
submitted to a quality control.
mEASUREmENTS AND ASSESSmENTS 
CASE DEFINITION
RMD diagnoses were performed according to the
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) classification
criteria for RA14; the ACR criteria for knee OA15, hip
OA16, hand OA17, FM18 , SLE19 and gout20; the Assess-
ment of SpondyloArthritis international Society
(ASAS) criteria for axial and peripheral SpA21-23; and
the Bird criteria for PMR24. PD was defined as a regional
pain syndrome affecting muscles, tendons, bursas or
periarticular soft tissues, with or without evidence of
joint or bone involvement. The following PDs were
specifically searched: tenosynovitis, adhesive capsuli-
tis of the shoulder, enthesopathies, bursitis, palmar or
plantar fasciitis, and carpal or tarsal tunnel syndrome,
present at the time of the interview. The PD diagnosis
was established based on expert opinion after review-
ing clinical history, physical exam, ultrasound and
electromyography (when available). OP was defined
by decision of the rheumatologist based on the pre -
sence of at least one of the following: previous fragili-
ty fracture, self-reported OP diagnosis, current OP
treatment or fulfillment of the WHO criteria25 when
lum bar and/or femoral neck dual energy X-ray absorp-
tiometry (DEXA) was available. Low back pain (LBP)
was defined solely by self-reported symptoms.
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SECONDARY VARIABLES DESCRIPTION
In the 1st phase of EpiReumaPt, subjects were asked
about their socio-demographic data (age, gender, eth-
nicity, education, marital status), socio-economic pro-
file (measures of wealth [used to generate income quin-
tiles], household income, work status) and life style
habits (alcohol and coffee intake, current smoking and
physical exercise). Work disability was evaluated by
absenteeism, presenteeism, early retirement and un-
employment due to work disability. Healthcare re-
source consumption data was collected considering
the number and type of outpatient clinic visits, hospi-
talizations, homecare assistance and other needs for
healthcare services in the previous 12 months. 
Health-related quality of life was evaluated using
the European Quality of Life questionnaire with five di-
mensions and three levels (EQ-5D-3L)26, 27 and also the
Short Form (36) Health Survey (SF-36)28. Physical
function was assessed by the Health Assessment Ques-
tionnaire (HAQ)29, anxiety and depression were as-
sessed by the Hospital Anxiety and Depression Scale
(HADS)30. We used Portuguese validated versions of
all these assessment scales. Anthropometric data (self-
reported weight and height) and self-reported chro nic
diseases (high cholesterol level, high blood pressure,
allergy, gastrointestinal disease, mental disease, cardiac
disease, diabetes, thyroid and parathyroid disease,
urolithiasis, pulmonary disease, hyperuricemia, neo-
plastic disease, neurologic disease, hypogonadism)
were also searched. Finally, information regarding
pharmacological and non-pharmacological therapies
was collected. 
In the 2nd phase of EpiReumaPt, data concerning
the medical history and physical examination were col-
lected. Questions about previous diagnosis of RMD,
medication and the need for medical visits due to RMD
symptoms in the previous year were also performed.
Validated instruments (eg. disease activity score 28
(DAS28) for RA and knee injury and osteoarthritis out-
come score (KOOS) for knee OA) were applied by the
rheumatologist according to the patient diagnosis.
BLOOD SAMPLING
A blood sample was drawn whenever subjects atten -
ded the second phase of the EpiReumaPt study and
signed the informed consent for the procedure. Pa-
tients with known hepatitis C, HIV infection or debi -
litating conditions were excluded. A 15-25 ml whole
blood sample was obtained; serum was separated by
centrifuging (800g, 10 minutes) the sample in the mo-
bile van and kept kept in the fridge at 4ºC. Blood sam-
ples from 3,664 participants were sent in a cooler on
the same day or within two days12 to Biobanco-IMM.
Serum and whole blood samples where aliquoted in
250µL and 2mL respectively and stored at -80ºC. DNA
extraction was performed by Qiacube (Qiagen, Ven-
lo, Netherlands) from 200µL of the whole blood. The
DNA was stored at -80ºC in 100µL aliquots. The 
content of the EpiReumaPt biobank is described in
Table III. Serum and whole blood samples were also
sent to the Central Diagnostic Laboratory Germano de
Sousa (Lisbon, Portugal), if deemed necessary by the
rheumatologist to perform laboratory tests. 
LABORATORY PROCEDURES
The different laboratorial paramethers were measures
according to the respective manufacturer's instruc-
tions: rheumatoid factor was measured by chemilu-
minescence; uric acid was quantified by a modifica-
tion of uricase method first published by Bulger and
Johns, modified by Kalckar; C-reactive protein was de-
termined by immunoturbidimetric method; urea was
measured by kinetic enzymatic method urease / gluta-
mate dehydrogenase; total creatine kinase (CK) was
measured by creatinine phosphate method; and com-
plement fractions C3 and C4 were detected by tur-
bidimetry, on an Dimension Vista 1500 Intelligent Lab
System (Siemens, Erlangen, Germany), applying
reagents from Siemens (Siemens, Erlangen, Germany).
Thyroid stimulating hormone (TSH) and Free thyroxi -
ne (FT4) were detected by chemiluminescence, on an
Advia Centaur XP (Siemens, Erlangen, Germany), ap-
plying reagents from Siemens (Siemens, Erlangen, Ger-
many). Antibodies against Cyclic Citrullinated Pep-
tides (anti-CCP) and antibodies against double strand-
ed DNA (anti-dsDNA) were measured by automated
fluoroimmunoassay, on an Immunocap250 (Thermo
Scientific, Uppsala, Sweden), applying reagents from
ELiA-Phadia (Thermo Scientific, Uppsala, Sweden).
Human Leukocyte Antigen-B27 (HLA-B27) was mea-
sured flow cytometry, on a FacsCalibur (Becton Dick-
inson, New Jersey, USA), applying reagents from BD
Bioscience (Becton Dickinson, New Jersey, USA).
Antinuclear antibodies (ANA) were measured by in-
direct fluoroimmunoassay, applying reagents from Eu-
roimmun (Euroimmun, Luebeck, Germany). Full
blood count and erythrocyte sedimentation rate (ESR)
were measured in whole blood samples. Hemoglobin
was quantified by Surfactant Sodium Lauryl Sulfate
Colorimetric, Mean Corpuscular Volume (MCV) was
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
116
epiReuMApt – the study of RheuMAtic And MusculoskeletAl diseAses in poRtugAl: A detAiled view of the Methodology 
measured by flow cytometry with hydrodynamic fo-
cusing, and leukocytes, lymphocytes and neutrophils
were measured by flow cytometry with side light scat-
ter, forward scatter and fluorescence intensity. ESR was
measured by microphotometry capillary flow.
PERIPHERAL DXA PROCEDURES
All participants who attended the second phase of the
study had a wrist DXA at the mobile unit on a PIXITM
LUNAR device (a peripheral Instantaneous X-ray Ima -
ger). This procedure provided precise assessment of
bone mineral density (BMD) with excellent image reso -
lution (0.2 mm pixels). PIXI is a peripheral densito-
meter that allows the operator to examine both the cal-
caneus and the forearm. PIXI employs the dual-energy
x-ray absorptiometry technique. A total of 3,342 par-
ticipants had a forearm bone mineral density evalua-
tion.
X- RAY PROCEDURES
Participants who attended the second phase had per-
formed wrist and calcaneus X-ray and bone mineral
assessment on a high resolution digital X-Ray machine
(D3A, France) in the mobile unit, in order to assess
bone microanalysis (BMA). Moreover, X-rays of the af-
fected joint or joints were also performed on BMA
high-resolution digital X-ray machine (D3A, France) as
requested by the rheumatologist. The content of the
EpiReumaPt imaging reservoir is described in Table III.
STATISTICAl ANAlySIS 
EpiReumaPt was designed to obtain a representative
sample of the Portuguese population. This population
will be subject of many other future analyses. Exactly
in order to guarantee its representativity, the design ef-
fect will need to be taken into account. This can be
achieved by using weighted proportions that have, for
this matter, been computed.
For the main sample, the initial extrapolation
weights were calculated as the inverse of the inclusion
probabilities, taking into account the sampling design,
i.e., a stratified two-stage cluster sampling design. The
stratification was based on the seven NUTS II regions
and on five classes of the number of inhabitants per lo-
cality (<2,000; 2,000-9,999; 10,000-19,999; 20,000-
99,999; >99,999). In each stratum, the first sampling
stage consisted in the selection of localities with a
proba bility proportional to its size (number inhabi-
tants aged 18 years old or more), except for localities
where the number of inhabitants was larger than
20,000, where all the localities were selected. In the
second stage, households were selected using a pseu-
do-random selection procedure equivalent to the equal
probability selection. These weights were submitted
to a calibration process by crossing region (seven class-
es), size of locality (five classes), gender (two classes)
and seven age categories (18-25, 26-35, 36-45, 46-55,
56-65, 66-75 and ≥76 years old). This procedure was
used to reproduce the known population totals for the
crossing margins of these four variables.
A sub-sample was drawn selecting all individuals
with positive screening for RMDs and 20% of those
with negative screening. For this sub-sample, inclu-
sion probabilities were calculated considering the re-
sult of the screening and adjustment for non-response.
This last adjustment was used because not all indivi -
duals selected for the second phase actually attended
the assessment by the rheumatologist. The basic ex-
trapolation weights obtained from these procedures
were again submitted to a calibration process by cross-
ing two classes of region (one collecting all the main-
land regions and a different one gathering the two au-
tonomic regions), gender (2 classes), four age cate-
gories (resulting from the aggregation of the original
classes in 18-35, 36-55, 56-75 and ≥76 years old) and
result of the RMD screening (positive/negative) in or-
der to reproduce the known national totals for the
crossing margins of these four variables. The decision
on the variables used for this second stage calibration
was based on a generalized linear model (positive
diagnos tic for several rheumatic diseases was used as
dependent variable) that identified the most impor-
tant criteria related to the prevalence of RMDs. These
weighted proportions will be used in several future
analyses, including the estimation of the prevalence of
the RMDs (study’s primary objective), which will be a
matter of a separate manuscript. 
EThICAl ISSUES AND PERSONAl 
PROTECTION
The EpiReumaPt study was performed according to
the principles established by the Declaration of Helsin-
ki. The study was reviewed and approved by the Na-
tional Committee for Data Protection (Comissão Na-
cional de Proteção de Dados) and by the NOVA Medical
School Ethics Committee. Ethical Committees of Re-
gional Health Authorities (ARS) also reviewed and ap-
proved the study. According to the Portuguese law, all
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subjects provided informed consented to participate
in the EpiReumaPt study. Individuals also consented to
give a blood sample for storage in Biobanco-IMM and
to be re-contacted if needed. Data protection was as-
sured by a data encryption process, which kept the
confidentiality and anonymity of each study subject.
Decryption was only possible with a secure password
only known by the Principal Investigator. This study
was conducted according to the good practices in re-
search.
REPORTING Of DIAGNOSIS AND TEST 
RESUlTS
During the assessment by the rheumatologist in phase
2, all patients with a new diagnosis of a chronic in-
flammatory rheumatic disease were referred to a
rheumatology center for follow-up. Other non-in-
flammatory newly diagnosed RMDs were referred to
the primary care physician. Each participant who per-
formed laboratory tests received a letter reporting the
test results. If a clinically significant abnormality was
depicted in the laboratorial results or X-rays, the par-
ticipant was also advised to see his/her doctor for fur-
ther investigation.
RESUlTS
The EpiReumaPt population is comparable to the Por-
tuguese population, as confirmed with data from the
Portuguese National Institute of Statistics (Census
2011)13, 31 (Table I). 
PARTICIPATION ANAlySIS
The EpiReumaPt study recruited 10,661 subjects and
64% had a positive screening for at least one RMD.
Moreover, out of the 8,152 eligible subjects, 3,877 en-
tered the second phase and were evaluated by a
rheumatologist. Individuals who attended the obser-
vation by the rheumatologist did not differ from those
who did not except for the screening diagnosis, age
group, gender and residence region according to the
NUTS II (Table II). These variables were considered in
the weighted model used to calculate the prevalence of
RMD. Furthermore, a sensitivity analysis was per-
formed and no differences in health status (including
quality of life and functional status) were found be-
tween participants and dropouts of the second phase
according to age groups, NUTS II and comorbidities
(data not shown).
DISCUSSION
EpiReumaPt is the first large-scale epidemiological
population-based study that evaluated RMDs in Por-
tugal. EpiReumaPt has a unique study design: the first
phase with a face to face questionnaire that aimed at
screening for the presence of RMD symptoms and spe-
cific RMDs; the second phase, comprising a clinical
observation performed by rheumatologists in primary
care units near the participants’ residence in order to
have the RMD diagnosis firmly established by a spe-
cialist; and the third phase, consisting of a rigorous
case review that aimed to homogenize the diagnostic
criteria and validate the definitive RMD diagnosis.
With this study design we were able to diagnosis new
RMDs, to correct the misinformation of some self-re-
ported diagnosis and to refine RMDs with a standardi -
zed case definition.
EpiReumaPt has also unique features when com-
pared to other studies performed in Portugal and
abroad1,2,4,32-36: It is a population-based study, with a
representative sample of the Portuguese population
and it covers an extensive range of topics that go be-
yond rheumatology. Unlike the recruitment performed
by mail as in the Spanish (Episer)37 and the Greek stu -
dies5, 38 that also evaluated the prevalence of RMD, re-
cruitment in EpiReumaPt was done by a random route
technique with a face to face interview, which reduced
selection bias. The EpiReumaPt screening algorithm
was specifically developed for this study and designed
to be highly sensitive in order to capture the maximum
number of RMDs cases. Finally, our case definition in-
cluded the most recent classification criteria for seve -
ral RMDs such as the classification criteria of the
ACR/EULAR for RA14 and the ASAS criteria for SpA21,23.
A comparison with Census 2011 allowed the deve -
lopment of different weights to be applied in the sam-
ples from 1st and 2nd phases, which will improve the
accu racy of further analyses and estimates. 
The concerted action from research groups, health
and governmental authorities, pharmaceutical com-
panies, the SPR and the population has resulted in a
very large database and has triggered extensive re-
search activities and collaborations. EpiReumaPt has
initiated collaboration with various research groups in
Portugal and other European countries and in the USA.
Procedures for data access are established, and a de -
dicated team of researchers is currently working on
EpiReumaPt data covering studies within a wide range
of medical topics. Moreover, the EpiReumaPt image
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TABlE I. SOCIO-DEmOGRAPhIC AND hEAlTh RElATED ChARACTERISTICS Of ThE ADUlT PORTUGUESE 
POPUlATION: EPIREUmAPT (1ST AND 2ND PhASE POPUlATIONS) AND CENSUS 2011 POPUlATIONS 
(PORTUGUESE POPUlATION)
1st phase study population 2nd phase study population
Demographic characteristics n=10,661 n=3,877 CENSUS 2011
Gender (female) 6,551 (52.6%) 2,630 (52.5%) 4,585,118 (53.0%)
Age group
18-29  1,182 (22.1%) 190 (21.0%) 1,470,782 (17.0%)
30-39 1,511 (18.8%) 403 (19.3%) 1,598,250 (18.5%)
40-49 1,906 (17.3%) 680 (18.2%) 1,543,392 (17.8%)
50-59 1,801 (14.8%) 818 (14.7%) 1,400,011 (16.2%)
60-69 1,915 (12.9%) 914 (13.4%) 1,186,442 (13.7%)
70-74 849 (5.8%) 376 (5.3%) 496,438 (5.7%)
≥75 1,497 (8.4%) 496 (8.0%) 961,925 (11.1%)
Ethnicity/Race
Caucasian 10,342 (96.0%) 3,786 (93.3%)
Black 221 (3.4%) 64 (6.1%)
Asian 8 (0.1%) 2 (0.0%) No comparable data
Gipsy 20 (0.3%) 3 (0.1%)
Other 38 (0.3%) 13 (0.5%)
Education level 
>12 years 1,764 (20.4%) 508 (21.1%) 1,741,567 (20.1%)
10-12 years 1,920 (23.8%) 575 (23.2%) 1,560,958 (18.0%)
5-9 years 2,175 (22.6%) 775 (22.4%) 2,134,401 (24.6%)
0-4 years 4,726 (33.2%) 1,997 (33.4%) 3,239,724 (37.4%)
NUTS II
Norte 3,122 (34.9%) 1,050 (37.2%) 3,007,823 (34.7%)
Centro 1,997 (22.8%) 856 (19.8%) 1,938,815 (22.4%)
Lisboa 2,484 (26.7%) 708 (29.6%) 2,300,053 (26.6%)
Alentejo 669 (7.3%) 273 (5.8%) 633,691 (7.3%)
Algarve 352 (3.8%) 144 (3.1%) 370,704 (4.3%)
Azores 1,029 (2.2%) 420 (2.3%) 192,357 (2.2%)
Madeira 1,008 (2.3%) 426 (2.2%) 213,797 (2.5%)
Marital status
Single 1,935 (29.4%) 456 (32.2%)
Married 6,111 (50.2%) 2,460 (49.9%)
Divorced 810 (7.4%) 310 (7.3%) No comparable data
Widower 1,414 (8.2%) 550 (7.6%)
Consensual union 382 (4.8%) 99 (3.1%)
BMI
Underweight 167 (2.2%) 46 (1.1%)
Normal 4,063 (45.5%) 1,234 (46.4%)
No comparable data
Overweight 3,799 (35.1%) 1,485 (34.3%)
Obese 2,080 (17.1%) 924 (18.1%)
Socio-economics
Household income*
<500€ 1,994 (19.9%) 795 (21.8%)
501€ to 750€ 1,707 (21.7%) 710 (20.4%)
751€ to 1000€ 1,268 (18.8%) 511 (18.9%) No comparable data
1001€ to 1500€ 1,141 (17.2%) 403 (15.9%)
1501€ to 2000€ 657 (9.9%) 246 (10.3%)
Continues on the next page
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TABlE I. SOCIO-DEmOGRAPhIC AND hEAlTh RElATED ChARACTERISTICS Of ThE ADUlT PORTUGUESE 
POPUlATION: EPIREUmAPT (1ST AND 2ND PhASE POPUlATIONS) AND CENSUS 2011 POPUlATIONS 
(PORTUGUESE POPUlATION) – (CONTINUE)
1st phase study population 2nd phase study population
Demographic characteristics n=10,661 n=3,877 CENSUS 2011
2001€ to 2500€ 379 (5.9%) 118 (4.7%)
2501€ to 3000€ 222 (3.0%) 73 (4.7%)
3001€ to 4000€ 146 (1.8%) 43 (16%)
>4000€ 99 (1.9%) 26 (1.7%)
Employment status
Employed full-time 3,993 (42.8%) 1,221 (42.6%)
Employed part-time 345 (4.6%) 117 (3.5%)
Domestic worker 660 (3.9%) 286 (3.3%)
Unemployed 1,087 (12.0%) 390 (13.7%) No comparable data
Student 428 (8.4%) 58 (4.8%)
Temporally work disabled 160 (1.2%) 80 (12.5%)
Retired 3,758 (24.9%) 1,636 (26.4%)
Others 229 (2.2%) 89 (4.5%)
Quality of life EQ5D Score 0.83 ± 0.23 0.81 ± 0.24
No comparable data
HAQ (0-3) 0.26 ± 0.54 0.27 ± 0.53
Life Style Habits
Current coffee intake
None 3,374 (29.1%) 1,263 (30.2%)
1 to 3 6,364 (59.1%) 2,331 (59.5%) No comparable data
More than 3 908 (11.9%) 277 (10.4%)
Current alcohol intake 
Daily 2,050 (20.2%) 773 (20.8%)
Occasionally 3,967 (42.6%) 1,305 (46.0%) No comparable data
Never 4,625 (37.1%) 1,794 (33.2%)
Current smoking habits 
Daily 1,854 (23.2%) 526 (20.8%)
Occasionally 246 (2.7%) 67 (2.2%) No comparable data
Never 8,554 (74.1%) 3,282 (77.0%)
Physical exercise 3,499 (37.0%) 1,182 (37.3%) No comparable data
Number of comorbidities 
(self-reported) 1.55 ± 1.80 1.71 ± 1.83 No comparable data
High cholesterol level 3,360 (24.4%) 1,556 (25.4%)
High blood pressure 3,369 (23.1%) 1,528 (23.2%)
Allergy 2,287 (21.3%) 985 (23.6%)
Gastrointestinal disease 1,837 (14.9%) 907 (17.4%)
Mental disease 1,619 (12.9%) 764 (11.1%)
Cardiac disease 1,366 (10.5%) 641 (11.7%)
Diabetes 1,217 (8.3%) 539 (8.8%)
Thyroid and parathyroid disease 941 (7.0%) 484 (10.5%)
No comparable data
Renal colic 885 (7.0%) 426 (8.8%)
Pulmonary disease 637 (5.4%) 295 (6.0%)
Hyperuricemia 690 (5.2%) 332 (4.7%)
Neoplasic disease 439 (3.4%) 208 (3.6%)
Neurologic disease 418 (3.3%) 183 (3.7%)
Hypogonadism 90 (0.7%) 40 (0.6%)
*household income in the last month
Sample size is not constant due to missing data in: 1st Phase EpiReumaPt study: Ethnicity (n=10,629), Education level (n=10,585), Marital
status (n=10,652), BMI (n=10,109), Household income (n=7,613), EQ5D Score (n=10,596), Current coffee intake (n=10,646), Current alco-
hol intake (n=10,646), Current smoking habits (n=10,645), Physical exercise (n=10,654), Number of Comorbidities (n=9,601), High choles-
terol level (n=10,514), High blood pressure (n=10,582), Allergy (n=10,570), Gastrointestinal disease (n=10,572), Mental disease (n=10,593), 
Continues on the next page
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TABlE II. COmPARISON BETwEEN EPIREUmAPT SUBjECTS INClUDED IN PhASE 2 wITh ThOSE NOT 
PARTICIPATING DESPITE BEING ElIGIBlE
Second phase participants Second phase drop-outs
n=3,877 n=4,275
Individuals without Rheumatic Disease 224 (31.9%) 477 (68.0%)
(701 individuals selected to medical consultation)
Gender
Female 2,628 (67.8%) 2,784 (65.1%)
Age 57.10 (±15.48) 55.24 (±18.95)
NUTSII
Norte 1,050 (27.1%) 1,313 (30.7%)
Centro 856 (22.1%) 765 (17.9%)
Lisboa 708 (18.3%) 1,146 (26.8%)
Alentejo 273 (7.0%) 247 (5.8%)
Algarve 144 (3.7%) 132 (3.1%)
Azores 420 (10.8%) 335 (7.8%)
Madeira 426 (11.0%) 337 (7.9%)
Years of education 6.81 (±3.94) 6.98 (±4.17)
Household income
<500€ 795 (27.2%) 862 (28.9%)
501€ to 750€ 710 (24.3%) 674 (22.6%)
751€ to 1000€ 511 (17.5%) 463 (15.5%)
1001€ to 1500€ 403 (13.8%) 435 (14.6%)
1501€ to 2000€ 246 (8.4%) 232 (7.8%)
2001€ to 2500€ 118 (4.0%) 142 (4.8%)
2501€ to 3000€ 73 (2.5%) 81 (2.7%)
3001€ to 4000€ 43 (1.5%) 55 (1.8%)
>4000€ 26 (0.9%) 41 (1.4%)
Employment status
Full-time employee 1,221 (31.8%) 1,493 (35.2%)
Unemployed 390 (10.2%) 391 (9.2%)
Retired 1,636 (42.6%) 1,679 (39.6%)
Student 58 (1.5%) 149 (3.5%)
EQ5D 0.72 (±0.27) 0.75 (±0.27)
HAQ 0.50 (±0.64) 0.43 (±0.65)
Continues on the next page
Continuation
Cardiac Disease (n=10,563), Diabetes (n=10,587), Thyroid and parathyroid disease (n=10,557), Renal colic (n=10,543), 
Pulmonary disease (n=10,594), Hyperuricemia (n=10,458), Neoplasic disease (n=10,602), Neurologic disease (n=10,581), Hypogonadism
(n=10,445)
2nd phase EpiReumaPt study: Ethnicity (n=3,868), Education level (n=3,855), Marital status (n=3,875), BMI (n=3,689), Household income
(n=2,925), EQ5D Score (n=3,846), Current coffee intake (n=3,871), Current alcohol intake (n=3,871), Current smoking habits (n=3,871),
Physical exercise (n=3,874), Number of Comorbidities (n=3,398), High cholesterol level (n=3,825), High blood pressure (n=3,851), Allergy
(n=3,845), Gastrointestinal disease (n=3,835), Mental disease (n=3,855), Cardiac Disease (n=3,833), Diabetes (n=3,840), Thyroid and
parathyroid disease (n=3,834), Renal colic (n=3,835), Pulmonary disease (n=3,855), Hyperuricemia (n=3,799), Neoplasic disease (n=3,854),
Neurologic disease (n=3,847), Hypogonadism (n=3,785)
The data presented in the CENSUS 2011 columns was obtained from the National Institute of Statistics. 
NUTS II- Nomenclature of Territorial Units for Statistics (Norte, Centro, Alentejo, Algarve, Lisboa, Madeira and the Azores); BMI- Body Mass
Index; EQ5D- European Quality of Life questionnaire five dimensions three levels; HAQ- Health Assessment Questionnaire
The estimated values for the characteristics were obtained considering study design.
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TABlE II. COmPARISON BETwEEN EPIREUmAPT SUBjECTS INClUDED IN PhASE 2 wITh ThOSE NOT 
PARTICIPATING DESPITE BEING ElIGIBlE (CONTINUE)
Second phase participants Second phase drop-outs
n=3,877 n=4,275
Positive RMD screening diagnosis
Low back pain 648 (53.3%) 567 (46.7%)
Inflammatory low back pain 1,263 (55.4%) 1,015 (44.6%)
Spondyloarthritis 2,119 (52.5%) 1,919 (47.5%)
Rheumatoid arthritis 2,002 (54.2%) 1,694 (45.8%)
Osteoarthritis 2,660 (51.9%) 2,465 (48.1%)
Fibromyalgia 822 (56.9%) 623 (43.1%)
SLE 694 (54.2%) 587 (45.8%)
Gout 624 (53.6%) 539 (46.3%)
PMR 300 (59.3%) 206 (40.7%)
Osteoporosis 983 (52.4%) 894 (47.6%)
Periarticular disease 2,405 (53.1%) 2,127 (46.9%)
Self-reported previous RMD diagnosis 1,604 (43.1%) 1,310 (31.7%)
Rheumatoid arthritis 221 (59.1%) 153 (40.9%)
Spondyloarthritis 93 (60.4%) 61 (39.6%)
Psoriatic arthritis 14 (60.9%) 9 (39.1%)
Osteoarthritis 635 (54.3%) 535 (45.7%)
Osteoporosis 393 (54.5%) 328 (45.5%)
Gout 57 (65.5%) 30 (34.5%)
Polymyalgia rheumatica 11 (45.8%) 13 (54.2%)
SLE 11 (47.8%) 12 (52.2%)
Fibromyalgia 66 (68.0%) 31 (32.0%)
Periarticular diseases 224 (62.2%) 136 (37.8%)
Comorbidities
High cholesterol level 1,556 (40.7%) 1,410 (33.6%)
High blood pressure 1,528 (39.7%) 1,446 (34.2%)
Allergy 985 (25.6%) 910 (21.5%)
Gastrointestinal disease 907 (23.6%) 782 (18.5%)
Mental disease 764 (19.8%) 713 (16.8%)
Cardiac disease 641 (16.7%) 615 (14.5%)
Diabetes 539 (14.0%) 528 (12.4%)
Thyroid and parathyroid disease 484 (12.6%) 386 (9.1%)
Urolithiasis 426 (11.1%) 382 (9.1%)
Pulmonary disease 295 (7.6%) 259 (6.1%)
Hyperuricemia 332 (8.7%) 323 (7.7%)
Neoplasic disease 208 (5.4%) 192 (4.5%)
Neurologic disease 183 (4.8%) 203 (4.8%)
Hypogonadism 40 (1.1%) 43 (1.0%)
Rheumatic diseases 1,604 (43.1%) 1,310 (31.7%)
Number of Comorbidities 2.61 ± 2.10 2.09 ± 1.98
Sample size is not constant due to missing data in 
Second phase Participants: Years of Education (n=3, 867), Household income (n=2,925), Employment status (n=3, 839), EQ5D (n=3,846), 
Self-reported previous RMD diagnosis (n=3,171), Self-reported previous RMD diagnosis per disease (n=1,604), High cholesterol level (n=3,825), High
blood pressure (n=3,851), Allergy (n=3,845), Gastrointestinal disease (n=3,835), Mental disease (n=3,855), Cardiac Disease (n=3,833), Diabetes
(n=3,840), Thyroid and parathyroid disease (n=3,834), Renal colic (n=3,835), Pulmonary disease (n=3,855), Hyperuricemia (n=3,799), 
Continues on the next page
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and biobank reservoirs constitute a valuable tool to
perform a comprehensive approach to the pathophy -
siology and outcome research of several diseases.
A fundamental premise for population-based stu -
dies is high confidence and legitimacy felt by the study
population. The strategy to achieve and withhold this
confidence in the Portuguese population has been suc-
cessful, and resulted in high participation rates and en-
thusiastic public and political support for
EpiReumaPt12. The confidence and supportive attitude
from the population was the trigger to develop an on-
going cohort study with EpiReumaPt subjects39. The
follow-up of this population goes beyond RMDs. Seve -
ral other diseases and health related topics are being
explored in this cohort.
In conclusion, the strict and robust methodology of
EpiReumaPt allowed for a large amount of informa-
tion to be collected from each participant, and the in-
clusion of a large number of participants with a wide
age range covering an entire country adult population,
making EpiReumaPt the largest study on RMDs per-
formed in Portugal. Moreover, the follow-up of this
population is ongoing and now goes beyond RMDs.
EpiReumaPt will answer several health-related ques-
tions and will generate important evidence useful to
support health policies in Portugal. 
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Neoplasic disease (n=3,854), Neurologic disease (n=3,847), Hypogonadism (n=3,785), Rheumatic diseases (n=3,717), Number of Comorbidities
(n=3,398).
Second phase drop-outs: Years of education (n=4,253), Household income (n=2,985), Employment status (n=4,237), EQ5D (n=4,250), 
Self-reported previous RMD diagnosis (n=4,131), Self-reported previous RMD diagnosis per disease (n=1,307), High cholesterol level (n=4,202),
High blood pressure (n=4,233), Allergy (n=4,233), Gastrointestinal disease (n=4,235), Mental disease (n=4,235), Cardiac Disease (n=4,228),
Diabetes (n=4,250), Thyroid and parathyroid disease (n=4,227), Renal colic (n=4,211), Pulmonary disease (n=4,238), Hyperuricemia (n=4,172),
Neoplasic disease (n=4,249), Neurologic disease (n=4,233), Hypogonadism (n=4,177), Rheumatic diseases (n=4,131), Number of Comorbidities
(n=3,793).
Positive Screening Low Back Pain (n=1,215), Inflammatory Low Back Pain (n=2,278), Spondyloarthritis (n=4,038), Rheumatoid Arthritis
(n=3,696), Osteoarthritis (n=5,125), Fibromyalgia (n=1,445), SLE (n=1,281), Gout (n=1,163), PMR (n=506), Osteoporosis (n=1,877),
Periarticular Pathology (n=4,532).
Regarding the acronyms NUTS II stands for the Nomenclature of Territorial Units for Statistics (Norte, Centro, Alentejo, Algarve, Lisboa, Madeira
and the Azores), EQ5D refers to European Quality of Life questionnaire five dimensions three levels, HAQ stands for Health Assessment
Questionnaire, and SLE - systemic lupus erythematosus. 
TABlE III. ThE EPIREUmAPT BIOBANk AND 
ImAGING RESERvOIR 
EpiReumaPt biobank n Volume per aliquot
Serum 21,219 250 µL
Whole blood 7,476 2 mL
DNA 3,608 100 µL
EpiReumaPt imaging reservoir
X-ray area n
Wrists (BMA) 2,422
Calcaneus (BMA) 2,228
Hands 438
Hips 122
Knees 479
Lumbar spine 1,265
Thoracic spine 691
Cervical spine 206
BMA: bone mineral assessment
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